In an interview with CNBC, Merck CEO Rob Davis expressed optimism about the future manufacturing efficiency of the company's personalized cancer vaccine in collaboration with Moderna. Currently, the production process takes about six weeks, but Davis believes this timeline will decrease as they refine their methods.
The vaccine is designed to target specific mutations in individual tumors, which complicates production but aims to enhance the immune response against cancer. This innovation is particularly significant as Merck prepares for the expiration of Keytruda's core patent in December 2028, a drug that has been pivotal in cancer treatment.
To mitigate the potential revenue decline from Keytruda, Merck is investing heavily in research and development, including a new 120,000-square-foot facility in Pennsylvania, and pursuing external acquisitions totaling $65 billion over five years. Additionally, Merck is facing legal challenges regarding a new subcutaneous formulation of Keytruda in Europe, which could impact its market presence.
Despite these challenges, the company is also launching new drugs, including Winrevair for a rare lung disease and Lipfendra for cholesterol management, as part of its strategy to diversify its portfolio and sustain growth